TP53 and neoplasm: Importantly, tumor development studies in laboratory mice have demonstrated that deletion of Cdkn1a inhibits lymphoma in Trp53-deficient [28], Atm-deficient [29] and normal mice [30], rather than promoting lymphoma as one might expect from the loss of a tumor suppressor gene.